Analysts reiterate buy rating on Opko Health with $3 price target, highlighting significant developments.
From Yahoo Finance: 2025-06-24 15:52:00
Opko Health Inc. (NASDAQ:OPK) is noted as one of the 13 best long-term penny stocks to buy by analysts. Piper Sandler reiterated a Buy rating with a $3.00 price target following the company’s fiscal Q1 2025 results announcement. Significant developments were highlighted in the report.
The company announced the sale of its BioReference laboratory testing businesses for up to $225 million, with a $192.5 million payout at closing and up to $32.5 million in a performance-based earnout. This sale focused on oncology and oncology-related clinical testing services.
Opko Health Inc. (NASDAQ:OPK) revealed a collaboration agreement with Entera Bio to advance oral GLP-1/glucagon tablet candidates for metabolic disorders and obesity treatment. The company’s ModeX is progressing its immuno-oncology and immunology portfolio with four potential clinical candidates.
As a biopharmaceutical and diagnostics company, Opko Health Inc. (NASDAQ:OPK) offers healthcare services through its Diagnostics and Pharmaceuticals segments. While OPK shows investment potential, certain AI stocks may offer greater upside potential and less downside risk, according to analysts.
For those seeking undervalued AI stock opportunities, a free report on the best short-term AI stock is available. Opko Health Inc. (NASDAQ:OPK) is mentioned in the context of its potential as an investment amidst other market trends and opportunities for growth.
Read more: Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT